FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132429302> ?p ?o ?g. }

• W2132429302 abstract "Abstract Background Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been demonstrated. A study was designed to investigate the safety of imatinib and its efficacy in preventing hematological relapse and improving disease-free survival (DFS) when administered after allogeneic hematopoietic stem cell transplantation (allo-HCT). Methods Patients with Ph + ALL that received allo-HCT were enrolled in the study. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to detect BCR-ABL transcript levels. Imatinib therapy was initiated if patient neutrophil counts were > 1.0 × 10 9 /L and platelet counts were > 50.0 × 10 9 /L, or if they displayed either elevated BCR-ABL transcript levels in two consecutive tests, or a BCR-ABL transcript level ≥ 10 -2 after initial engraftment. Patients receiving imatinib after relapse were assigned to the non-imatinib group. The imatinib treatment was scheduled for 3–12 months, until BCR-ABL transcript levels were negative at least for three consecutive tests or complete molecular remission was sustained for at least 3 months. Results A total of 82 patients were enrolled. Sixty-two patients initiated imatinib therapy post-HCT. Imatinib therapy was initiated at a median time of 70 days post-HCT. Grade 3–4 adverse events (AEs) occurred in 17.7% of patients. Ten patients (16.1%) terminated imatinib therapy owing to AEs. Among the patients in imatinib and non-imatinib groups, the estimated 5-year relapse rate was 10.2% and 33.1% (p = 0.016), and the 5-year probability of DFS was 81.5% and 33.5% (p = 0.000) with the median follow-up of 31 months (range, 2.5-76 months) and 24.5 months (range, 4–72 months), respectively. Multivariate analysis identified imatinib maintenance therapy post-HCT as an independent prognostic factor for DFS (p = 0.000, hazard ratio [HR] =4.8) and OS (p = 0.000, HR = 6.2). Conclusions These results indicate that relapse rate can be reduced and DFS may be improved in Ph + ALL patients with imatinib maintenance therapy after HCT. BCR-ABL monitoring by qRT-PCR can guide maintenance therapy with imatinib including initiation time and treatment duration after allo-HCT." @default.
• W2132429302 created "2016-06-24" @default.
• W2132429302 creator A5002188808 @default.
• W2132429302 creator A5021880262 @default.
• W2132429302 creator A5041756956 @default.
• W2132429302 creator A5056446917 @default.
• W2132429302 creator A5061407928 @default.
• W2132429302 creator A5065894155 @default.
• W2132429302 creator A5067347223 @default.
• W2132429302 creator A5072208411 @default.
• W2132429302 creator A5078632164 @default.
• W2132429302 creator A5079594267 @default.
• W2132429302 creator A5087610827 @default.
• W2132429302 creator A5088917859 @default.
• W2132429302 date "2012-06-08" @default.
• W2132429302 modified "2023-10-14" @default.
• W2132429302 title "Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia" @default.
• W2132429302 cites W1644813534 @default.
• W2132429302 cites W1975127056 @default.
• W2132429302 cites W1977794804 @default.
• W2132429302 cites W1984877560 @default.
• W2132429302 cites W2000116184 @default.
• W2132429302 cites W2003041273 @default.
• W2132429302 cites W2036724262 @default.
• W2132429302 cites W2036862498 @default.
• W2132429302 cites W2068420766 @default.
• W2132429302 cites W2076165479 @default.
• W2132429302 cites W2079110478 @default.
• W2132429302 cites W2079540984 @default.
• W2132429302 cites W2080380323 @default.
• W2132429302 cites W2096336184 @default.
• W2132429302 cites W2104073210 @default.
• W2132429302 cites W2110661347 @default.
• W2132429302 cites W2121484324 @default.
• W2132429302 cites W2137780481 @default.
• W2132429302 cites W2141324982 @default.
• W2132429302 cites W2148207894 @default.
• W2132429302 cites W2148854558 @default.
• W2132429302 cites W2153151008 @default.
• W2132429302 cites W2153801741 @default.
• W2132429302 cites W2161936058 @default.
• W2132429302 cites W2163878076 @default.
• W2132429302 cites W2415399318 @default.
• W2132429302 cites W2558003337 @default.
• W2132429302 cites W2597177616 @default.
• W2132429302 doi "https://doi.org/10.1186/1756-8722-5-29" @default.
• W2132429302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3407007" @default.
• W2132429302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22682059" @default.
• W2132429302 hasPublicationYear "2012" @default.
• W2132429302 type Work @default.
• W2132429302 sameAs 2132429302 @default.
• W2132429302 citedByCount "87" @default.
• W2132429302 countsByYear W21324293022012 @default.
• W2132429302 countsByYear W21324293022013 @default.
• W2132429302 countsByYear W21324293022014 @default.
• W2132429302 countsByYear W21324293022015 @default.
• W2132429302 countsByYear W21324293022016 @default.
• W2132429302 countsByYear W21324293022017 @default.
• W2132429302 countsByYear W21324293022018 @default.
• W2132429302 countsByYear W21324293022019 @default.
• W2132429302 countsByYear W21324293022020 @default.
• W2132429302 countsByYear W21324293022021 @default.
• W2132429302 countsByYear W21324293022022 @default.
• W2132429302 countsByYear W21324293022023 @default.
• W2132429302 crossrefType "journal-article" @default.
• W2132429302 hasAuthorship W2132429302A5002188808 @default.
• W2132429302 hasAuthorship W2132429302A5021880262 @default.
• W2132429302 hasAuthorship W2132429302A5041756956 @default.
• W2132429302 hasAuthorship W2132429302A5056446917 @default.
• W2132429302 hasAuthorship W2132429302A5061407928 @default.
• W2132429302 hasAuthorship W2132429302A5065894155 @default.
• W2132429302 hasAuthorship W2132429302A5067347223 @default.
• W2132429302 hasAuthorship W2132429302A5072208411 @default.
• W2132429302 hasAuthorship W2132429302A5078632164 @default.
• W2132429302 hasAuthorship W2132429302A5079594267 @default.
• W2132429302 hasAuthorship W2132429302A5087610827 @default.
• W2132429302 hasAuthorship W2132429302A5088917859 @default.
• W2132429302 hasBestOaLocation W21324293021 @default.
• W2132429302 hasConcept C104317684 @default.
• W2132429302 hasConcept C126322002 @default.
• W2132429302 hasConcept C138626823 @default.
• W2132429302 hasConcept C143998085 @default.
• W2132429302 hasConcept C194409129 @default.
• W2132429302 hasConcept C197934379 @default.
• W2132429302 hasConcept C203014093 @default.
• W2132429302 hasConcept C2777408962 @default.
• W2132429302 hasConcept C2777583451 @default.
• W2132429302 hasConcept C2778461978 @default.
• W2132429302 hasConcept C2778729363 @default.
• W2132429302 hasConcept C2778904597 @default.
• W2132429302 hasConcept C28328180 @default.
• W2132429302 hasConcept C2911091166 @default.
• W2132429302 hasConcept C3019892230 @default.
• W2132429302 hasConcept C54355233 @default.
• W2132429302 hasConcept C55493867 @default.
• W2132429302 hasConcept C71924100 @default.
• W2132429302 hasConcept C86803240 @default.
• W2132429302 hasConcept C90924648 @default.
• W2132429302 hasConceptScore W2132429302C104317684 @default.
• W2132429302 hasConceptScore W2132429302C126322002 @default.

• next